Pharming Group N.V. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 35 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pharming Group N.V. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Pharming Group N.V. - Product Pipeline Review - 2015', provides an overview of the Pharming Group N.V.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharming Group N.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pharming Group N.V. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pharming Group N.V.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Pharming Group N.V.'s pipeline products

Reasons to buy

- Evaluate Pharming Group N.V.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pharming Group N.V. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pharming Group N.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pharming Group N.V. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharming Group N.V.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Pharming Group N.V. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Pharming Group N.V. Snapshot 5
Pharming Group N.V. Overview 5
Key Information 5
Key Facts 5
Pharming Group N.V. - Research and Development Overview 6
Key Therapeutic Areas 6
Pharming Group N.V. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pharming Group N.V. - Pipeline Products Glance 10
Pharming Group N.V. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Pharming Group N.V. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Pharming Group N.V. - Drug Profiles 13
C1 esterase inhibitor (recombinant) 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Recombinant Enzyme to Replace Alpha Glucosidase for Pompe Disease 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Recombinant Enzyme to Replace Factor IX for Hemophilia B 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Recombinant Protein to Replace Factor VIII for Hemophilia A 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Pharming Group N.V. - Pipeline Analysis 23
Pharming Group N.V. - Pipeline Products by Target 23
Pharming Group N.V. - Pipeline Products by Route of Administration 24
Pharming Group N.V. - Pipeline Products by Molecule Type 25
Pharming Group N.V. - Pipeline Products by Mechanism of Action 26
Pharming Group N.V. - Recent Pipeline Updates 27
Pharming Group N.V. - Discontinued Pipeline Products 30
Discontinued Pipeline Product Profiles 30
fibrinogen 30
Pharming Group N.V. - Company Statement 31
Pharming Group N.V. - Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35

List of Tables

Pharming Group N.V., Key Information 5
Pharming Group N.V., Key Facts 5
Pharming Group N.V. - Pipeline by Indication, 2015 7
Pharming Group N.V. - Pipeline by Stage of Development, 2015 8
Pharming Group N.V. - Monotherapy Products in Pipeline, 2015 9
Pharming Group N.V. - Phase II, 2015 10
Pharming Group N.V. - Preclinical, 2015 11
Pharming Group N.V. - Discovery, 2015 12
Pharming Group N.V. - Pipeline by Target, 2015 23
Pharming Group N.V. - Pipeline by Route of Administration, 2015 24
Pharming Group N.V. - Pipeline by Molecule Type, 2015 25
Pharming Group N.V. - Pipeline Products by Mechanism of Action, 2015 26
Pharming Group N.V. - Recent Pipeline Updates, 2015 27
Pharming Group N.V. - Discontinued Pipeline Products, 2015 30
Pharming Group N.V., Subsidiaries 33